Repurposed antifungal exhibits promising results

A novel oral formulation of itraconazole designed to improve bioavailability is leveraging its activity as a Hedgehog pathway inhibitor to provide a low toxicity, effective treatment for patients with BCC Nevus Syndrome. Data show potential for rapid therapeutic benefit.

Source: Dermatology Times - November 2, 2017 Category: Dermatology Source Type: news